Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases
Year: 2025
Type: article
Language: en
Topic: Lung Cancer Research Studies
Authors and affiliations:
raw_author_name: Jing Chen
raw_affiliation_strings: Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Department of Pulmonary Oncology, The First People's Hospital of Foshan, Foshan, Guangdong, China
State Key Laboratory of Oncology in South China
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
raw_author_name: Yin Pan
raw_affiliation_strings: Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
State Key Laboratory of Oncology in South China
raw_author_name: Meichen Li
raw_affiliation_strings: Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
State Key Laboratory of Oncology in South China
raw_author_name: Hui Yu
raw_affiliation_strings: Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
State Key Laboratory of Oncology in South China
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
raw_author_name: Baishen Zhang
raw_affiliation_strings: Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
State Key Laboratory of Oncology in South China
Sun Yat-Sen University Cancer Center
raw_author_name: Mingjie Yu
raw_affiliation_strings: Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
State Key Laboratory of Oncology in South China
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
raw_author_name: Xue Hou
raw_affiliation_strings: Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Department of Medical Oncology, Sun Yat-Sen University Cancer Center
State Key Laboratory of Oncology in South China
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
raw_author_name: Likun Chen
raw_affiliation_strings: Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. chenlk@sysucc.org.cn
Department of Medical Oncology, Sun Yat-Sen University Cancer Center
State Key Laboratory of Oncology in South China